Gilead Sciences, the biotech company based out of California that created one of the first original treatments for COVID-19, has set the price for remdesivir between $2,340 and $3,120 for a typical course treatment. While remdesivir has still yet to prove to reduce COVID-19 deaths, is does reduce the recovery time for patients when treated early with the drug. The varying drug prices depend on if patients are covered by government insurance or commercial health plans, with U.S. private insurers paying approximately $520 per vial. Gilead has also agreed to sell nearly all of its supply to the United States over the next three months.
Read more here.